The mechanism is unclear but, in both prostate and renal cancers and insulin resistance, is associated with high circulating levels of insulin-like growth factors (ILGF) and high levels of the hormone leptin - which activates several carcinogenic cellular pathways. The gene discussed is LEP; the disease is renal carcinoma.